Key facts
- Vivace Therapeutics’s last known valuation is $125.0M (Feb 2025).
- It has raised $105.0M across 4 recorded rounds; the latest was Later Stage VC (Series D) ($35.0M) in Feb 2025.
- Notable investors include Sequoia Capital, Hongshan Capital Group, RA Capital Management, Canaan Partners, Mission BioCapital — 11 tracked in total.
- Vivace Therapeutics has filed 5 Form Ds with the SEC since 2015, most recently Mar 2025 ($17.5M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Vivace Therapeutics
Funding rounds
4 roundsAbout Vivace Therapeutics
Operator of a small molecule drug discovery firm intended to introduce new treatments for cancer patients. The company creates therapies that target distinct biological pathways and function either alone or alongside existing drugs, enabling healthcare professionals to access additional options for cancers with limited treatment alternatives.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Mateo, CA, United States
- Founded
- 2014
- Employees
- 10
- Website
- vivacetherapeutics.com/
- Ownership
- Privately Held (backing)
Vivace Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vivace Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vivace Therapeutics in its N-PORT filings yet. We sweep new filings monthly.